155 related articles for article (PubMed ID: 15185468)
1. [Biventricular heart failure in patient treated with anthracycline in childhood: myocardial dysfunction is not always the cause].
Iarussi D; Martino V; Iacono C; Indolfi P; Muto R; Calabrò R
Ital Heart J Suppl; 2004 Apr; 5(4):294-7. PubMed ID: 15185468
[TBL] [Abstract][Full Text] [Related]
2. [Heart failure in a subject treated with anthracyclines in childhood: myocardial dysfunction is not always the only reason of it].
Iarussi D; Martino V; Iacono C; Indolfi P; Muto R; Calabrò R
Ital Heart J Suppl; 2004 Apr; 5(4):294-7. PubMed ID: 15346697
[TBL] [Abstract][Full Text] [Related]
3. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
4. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
[TBL] [Abstract][Full Text] [Related]
5. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
[TBL] [Abstract][Full Text] [Related]
6. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
8. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow MR; Billingham ME; Mason JW; Daniels JR
Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
[TBL] [Abstract][Full Text] [Related]
9. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
[TBL] [Abstract][Full Text] [Related]
11. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
12. Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.
Hutchinson RJ; Bailey C; Wood D; Donaldson MH
Cancer Treat Rep; 1978 Jun; 62(6):907-10. PubMed ID: 667866
[TBL] [Abstract][Full Text] [Related]
13. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
[TBL] [Abstract][Full Text] [Related]
14. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.
Chen C; Heusch A; Donner B; Janssen G; Göbel U; Schmidt KG
Klin Padiatr; 2009; 221(3):162-6. PubMed ID: 19437364
[TBL] [Abstract][Full Text] [Related]
15. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
16. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare.
Ward KM; Binns H; Chin C; Webber SA; Canter CE; Pahl E
J Heart Lung Transplant; 2004 Sep; 23(9):1040-5. PubMed ID: 15454169
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-induced cardiomyopathy.
Keefe DL
Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.
Simsir SA; Lin SS; Blue LJ; Gockerman JP; Russell SD; Milano CA
Ann Thorac Surg; 2005 Aug; 80(2):717-9. PubMed ID: 16039240
[TBL] [Abstract][Full Text] [Related]
19. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
[TBL] [Abstract][Full Text] [Related]
20. Reversible doxorubicin-induced congestive heart failure.
Cohen M; Kronzon I; Lebowitz A
Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
